Company · founded 2012
SignalRx Pharmaceuticals (United States)
San Diego, United States · signalrx.com
- Citations, last 5 years
- 3
- Works, last 5 years
- 2
- h-index
- 48
- Scientists listed
- 0
- Grants since 2016
- 4
Grants received
2019 · research · R43
Overcoming BTK inhibitor resistance in B-cell malignancies
Guillermo A Morales · SignalRx Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2022 · research · R41
Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity
Guillermo A Morales · SignalRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2017 · research · R41
Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
Donald Durden · SignalRx Pharmaceuticals (United States) · funded by National Institutes of Health
2015–2022 · research · R42
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523
Guillermo A Morales · SignalRx Pharmaceuticals (United States) · funded by National Institutes of Health